Bence Kovács - Academia.edu (original) (raw)

Uploads

Papers by Bence Kovács

Research paper thumbnail of Drugs Becoming Generics—The Impact of Genericization on the Market Performance of Antihypertensive Active Pharmaceutical Ingredients

International Journal of Environmental Research and Public Health, Sep 7, 2021

This article is an open access article distributed under the terms and conditions of the Creative... more This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY

Research paper thumbnail of The impact of scientific evidence and price level of hypertension drug therapies on their market performance – A Europe based analysis

Vezetéstudomány / Budapest Management Review, 2017

Research paper thumbnail of Gyógyszerkészítmények és hatóanyagok életútmenedzsmentje a magyar gyógyszeriparban

Research paper thumbnail of Drugs Becoming Generics—The Impact of Genericization on the Market Performance of Antihypertensive Active Pharmaceutical Ingredients

International Journal of Environmental Research and Public Health

To explore long-term changes in intra and inter-class choices between generic compounds, this pap... more To explore long-term changes in intra and inter-class choices between generic compounds, this paper investigates the market trends of two antihypertensive drug classes that have closely related pharmacological mechanisms—angiotensin convertase enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). We analysed the development of ACEI and ARB markets between 2001 and 2016 in nine European countries, covering the genericization transition periods of both therapeutic groups. The analysis was undertaken on the level of the active pharmaceutical ingredients (API) and focused on international and country-specific diffusion patterns. Comparison of ARB and ACEI therapies shows that although ARBs became off-patent during the observed period, and have a clinical advantage in terms of the adverse event profile over ACEIs, the increasing dominance of ARBs cannot be identified. One explanation is that ACEI therapies became generics earlier, relocating competition to the level of bran...

Research paper thumbnail of Drugs Becoming Generics—The Impact of Genericization on the Market Performance of Antihypertensive Active Pharmaceutical Ingredients

International Journal of Environmental Research and Public Health, Sep 7, 2021

This article is an open access article distributed under the terms and conditions of the Creative... more This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY

Research paper thumbnail of The impact of scientific evidence and price level of hypertension drug therapies on their market performance – A Europe based analysis

Vezetéstudomány / Budapest Management Review, 2017

Research paper thumbnail of Gyógyszerkészítmények és hatóanyagok életútmenedzsmentje a magyar gyógyszeriparban

Research paper thumbnail of Drugs Becoming Generics—The Impact of Genericization on the Market Performance of Antihypertensive Active Pharmaceutical Ingredients

International Journal of Environmental Research and Public Health

To explore long-term changes in intra and inter-class choices between generic compounds, this pap... more To explore long-term changes in intra and inter-class choices between generic compounds, this paper investigates the market trends of two antihypertensive drug classes that have closely related pharmacological mechanisms—angiotensin convertase enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). We analysed the development of ACEI and ARB markets between 2001 and 2016 in nine European countries, covering the genericization transition periods of both therapeutic groups. The analysis was undertaken on the level of the active pharmaceutical ingredients (API) and focused on international and country-specific diffusion patterns. Comparison of ARB and ACEI therapies shows that although ARBs became off-patent during the observed period, and have a clinical advantage in terms of the adverse event profile over ACEIs, the increasing dominance of ARBs cannot be identified. One explanation is that ACEI therapies became generics earlier, relocating competition to the level of bran...

Log In